Trial Profile
A Phase 1 study on single and multiple oral dose administration of ONO-2160/CD in healthy adult male subjects and on multiple oral dose administration of ONO-2160/CD in Parkinson's disease patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Aug 2016
Price :
$35
*
At a glance
- Drugs Carbidopa/ONO 2160 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Ono Pharmaceutical
- 15 Jul 2016 Status changed from active, no longer recruiting to completed.
- 07 Jun 2016 New trial record